Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia
AMERICAN JOURNAL OF HEMATOLOGY, vol.80, no.3, pp.213-215, 2005 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 80 Issue: 3
- Publication Date: 2005
- Doi Number: 10.1002/ajh.20432
- Journal Name: AMERICAN JOURNAL OF HEMATOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.213-215
- Hacettepe University Affiliated: Yes
Abstract
Gemtuzumab ozogamicin (GO; CMA-676; Mylotarg((TM))) is a chemotherapeutic agent approved for the treatment of CD33-positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno-occlusive disease has been reported to develop as a late complication of gemtuzumab ozogamicin treatment. A patient who developed Budd-Chiari Syndrome with hepatic vein thrombosis following treatment with GO is presented. This complication has not been previously reported, and it deserves to be considered as a possible adverse effect of gemtuzumab ozogamicin.